Detectable Serum Pro-opiomelanocortin-Derived Peptides in Bromocriptine-Sensitive Cushing Disease
暂无分享,去创建一个
M. Odawara | Takaaki Kobayashi | Y. Oki | M. Kanazawa | T. Miwa | N. Iwahashi | Y. Notoya | Koshi Tanaka | Masahiko Kume | K. Hiramine
[1] M. Minetto,et al. The corticotrophin‐releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome , 2003, Clinical endocrinology.
[2] M. Korbonits,et al. Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. , 2002, The Journal of clinical endocrinology and metabolism.
[3] A. Saiardi,et al. Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice. , 1998, Molecular endocrinology.
[4] R. Magallón,et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. , 1997, The New England journal of medicine.
[5] N. Colombo,et al. MR of corticotropin-secreting pituitary microadenomas. , 1994, AJNR. American journal of neuroradiology.
[6] K. Takakura,et al. Selective venous sampling directly from cavernous sinus in Cushing's syndrome. , 1993, The Journal of clinical endocrinology and metabolism.
[7] T. Mune,et al. Cortisol-suppressible dexamethasone-nonsuppressible cyclic Cushing's disease with evidence of clinical and biochemical remission with bromocriptine. , 1991, Endocrinologia japonica.
[8] S. Arimori,et al. A case of Cushing's disease successfully treated with bromocriptine. , 1990, Japanese journal of medicine.
[9] G. Besser,et al. MEGAVOLTAGE PITUITARY IRRADIATION IN THE MANAGEMENT OF CUSHING'S DISEASE AND NELSON'S SYNDROME: LONG‐TERM FOLLOW‐UP , 1989, Clinical endocrinology.
[10] A. Grossman,et al. A BROMOCRIPTINE‐RESPONSIVE CORTICOTROPH ADENOMA SECRETING α‐MSH IN A PATIENT WITH CUSHING'S DISEASE , 1988, Clinical endocrinology.
[11] C. Francalanci,et al. Cushing’s disease: clinical and laboratory response to bromocriptine therapy , 1984, Journal of endocrinological investigation.
[12] M. Nagata,et al. Identification of source of excessive ACTH production by improved selective venous sampling: simultaneous assay of PRL as a pituitary marker. , 1984, Endocrinologia japonica.
[13] M. Tagliaferri,et al. Cushing’s disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment , 1984, Journal of endocrinological investigation.
[14] S. Lamberts,et al. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. , 1982, The Journal of clinical endocrinology and metabolism.
[15] J. Deakin,et al. Influence of N-terminal acetylation and C-terminal proteolysis on the analgesic activity of beta-endorphin. , 1980, The Biochemical journal.
[16] D. Schteingart,et al. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. , 1980, Annals of internal medicine.
[17] R. Mains,et al. Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. , 1980, Endocrine reviews.
[18] M. Laudat,et al. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. , 1979, The New England journal of medicine.
[19] J. Melby,et al. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. , 1978, The Journal of clinical endocrinology and metabolism.
[20] K. Tanaka,et al. The nature of the immunoreactive lipotropins in human plasma and tissue extracts. , 1978, The Journal of clinical investigation.
[21] C. McMartin,et al. Purification and characterization of porcine corticotrophin-like intermediate lobe peptide. , 1974, The Journal of endocrinology.